Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
Background. Adalimumab (ADA) is effective for patients with Crohn’s disease (CD). However, there have been few reports on ADA therapy with respect to its relationship with pathologic findings and drug efficacy in biologically naïve CD cases. Methods. Fifteen patients with active biologically naïve...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2014/687257 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551602432507904 |
|---|---|
| author | Tsutomu Mizoshita Satoshi Tanida Hironobu Tsukamoto Keiji Ozeki Takahito Katano Hirotaka Nishiwaki Masahide Ebi Yoshinori Mori Eiji Kubota Hiromi Kataoka Takeshi Kamiya Takashi Joh |
| author_facet | Tsutomu Mizoshita Satoshi Tanida Hironobu Tsukamoto Keiji Ozeki Takahito Katano Hirotaka Nishiwaki Masahide Ebi Yoshinori Mori Eiji Kubota Hiromi Kataoka Takeshi Kamiya Takashi Joh |
| author_sort | Tsutomu Mizoshita |
| collection | DOAJ |
| description | Background. Adalimumab (ADA) is effective for patients with Crohn’s disease (CD). However, there have been few reports on ADA therapy with respect to its relationship with pathologic findings and drug efficacy in biologically naïve CD cases. Methods. Fifteen patients with active biologically naïve CD were treated with ADA. We examined them clinically and pathologically with ectopic MUC5AC expression in the lesions before and after 12 and 52 weeks of ADA therapy, retrospectively. Results. Both mean CD activity index scores and serum C-reactive protein values were significantly lower after ADA therapy (P<0.001). In the MUC5AC negative group, all cases exhibited clinical remission (CR) and endoscopic improvement at 52 weeks. In MUC5AC positive groups, loss of MUC5AC expression was detected in cases having CR and endoscopic improvement at 52 weeks, while remnant ectopic MUC5AC expression was observed in those exhibiting no endoscopic improvement and flare up after 52 weeks. Conclusions. ADA leads to CR and endoscopic improvement in biologically naïve CD cases. In addition, ectopic MUC5AC expression may be a predictive marker of flare up and endoscopic improvement in the intestines of CD patients. |
| format | Article |
| id | doaj-art-431717d2363149bb9ba11fd4ac89dc4c |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-431717d2363149bb9ba11fd4ac89dc4c2025-02-03T06:00:57ZengWileyGastroenterology Research and Practice1687-61211687-630X2014-01-01201410.1155/2014/687257687257Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic ImprovementTsutomu Mizoshita0Satoshi Tanida1Hironobu Tsukamoto2Keiji Ozeki3Takahito Katano4Hirotaka Nishiwaki5Masahide Ebi6Yoshinori Mori7Eiji Kubota8Hiromi Kataoka9Takeshi Kamiya10Takashi Joh11Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, JapanBackground. Adalimumab (ADA) is effective for patients with Crohn’s disease (CD). However, there have been few reports on ADA therapy with respect to its relationship with pathologic findings and drug efficacy in biologically naïve CD cases. Methods. Fifteen patients with active biologically naïve CD were treated with ADA. We examined them clinically and pathologically with ectopic MUC5AC expression in the lesions before and after 12 and 52 weeks of ADA therapy, retrospectively. Results. Both mean CD activity index scores and serum C-reactive protein values were significantly lower after ADA therapy (P<0.001). In the MUC5AC negative group, all cases exhibited clinical remission (CR) and endoscopic improvement at 52 weeks. In MUC5AC positive groups, loss of MUC5AC expression was detected in cases having CR and endoscopic improvement at 52 weeks, while remnant ectopic MUC5AC expression was observed in those exhibiting no endoscopic improvement and flare up after 52 weeks. Conclusions. ADA leads to CR and endoscopic improvement in biologically naïve CD cases. In addition, ectopic MUC5AC expression may be a predictive marker of flare up and endoscopic improvement in the intestines of CD patients.http://dx.doi.org/10.1155/2014/687257 |
| spellingShingle | Tsutomu Mizoshita Satoshi Tanida Hironobu Tsukamoto Keiji Ozeki Takahito Katano Hirotaka Nishiwaki Masahide Ebi Yoshinori Mori Eiji Kubota Hiromi Kataoka Takeshi Kamiya Takashi Joh Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement Gastroenterology Research and Practice |
| title | Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement |
| title_full | Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement |
| title_fullStr | Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement |
| title_full_unstemmed | Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement |
| title_short | Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement |
| title_sort | adalimumab treatment in biologically naive crohn s disease relationship with ectopic muc5ac expression and endoscopic improvement |
| url | http://dx.doi.org/10.1155/2014/687257 |
| work_keys_str_mv | AT tsutomumizoshita adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement AT satoshitanida adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement AT hironobutsukamoto adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement AT keijiozeki adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement AT takahitokatano adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement AT hirotakanishiwaki adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement AT masahideebi adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement AT yoshinorimori adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement AT eijikubota adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement AT hiromikataoka adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement AT takeshikamiya adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement AT takashijoh adalimumabtreatmentinbiologicallynaivecrohnsdiseaserelationshipwithectopicmuc5acexpressionandendoscopicimprovement |